Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2...

por Yuan, Li, Jia, Guo-Dong, Lv, Xiao-Fei, Xie, Si-Yi, Guo, Shan-Shan, Lin, Da-Feng, Liu, Li-Ting, Luo, Dong-Hua, Li, Yi-Fu, Deng, Shen-Wen, Guo, Ling, Zeng, Mu-Sheng, Cai, Xiu-Yu, Liu, Sai-Lan, Sun, Xue-Song, Li, Xiao-Yun, Li, Su-Chen, Chen, Qiu-Yan, Tang, Lin-Quan, Mai, Hai-Qiang
Publicado 2023